These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39293124)

  • 1. The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study.
    Sandgren S; Novakova L; Nordin A; Sabir H; Axelsson M; Malmeström C; Zetterberg H; Lycke J
    Mult Scler Relat Disord; 2024 Nov; 91():105894. PubMed ID: 39293124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study.
    Paul F; Calabresi PA; Barkhof F; Green AJ; Kardon R; Sastre-Garriga J; Schippling S; Vermersch P; Saidha S; Gerendas BS; Schmidt-Erfurth U; Agoropoulou C; Zhang Y; Seifer G; Petzold A
    Ann Clin Transl Neurol; 2021 Dec; 8(12):2235-2251. PubMed ID: 34792863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.
    Sandgren S; Novakova L; Nordin A; Axelsson M; Malmeström C; Zetterberg H; Lycke J
    Front Neurol; 2023; 14():1265354. PubMed ID: 37808497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
    Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
    J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal nerve fiber and ganglion cell complex layer thicknesses mirror brain atrophy in patients with relapsing-remitting multiple sclerosis.
    Glasner P; Sabisz A; Chylińska M; Komendziński J; Wyszomirski A; Karaszewski B
    Restor Neurol Neurosci; 2022; 40(1):35-42. PubMed ID: 35180139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy.
    Sotirchos ES; Gonzalez Caldito N; Filippatou A; Fitzgerald KC; Murphy OC; Lambe J; Nguyen J; Button J; Ogbuokiri E; Crainiceanu CM; Prince JL; Calabresi PA; Saidha S;
    Ann Neurol; 2020 Jun; 87(6):885-896. PubMed ID: 32285484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis.
    Gernert JA; Böhm L; Starck M; Buchka S; Kümpfel T; Kleiter I; Havla J
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    Behbehani R; Abu Al-Hassan A; Al-Salahat A; Sriraman D; Oakley JD; Alroughani R
    PLoS One; 2017; 12(2):e0172120. PubMed ID: 28192539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
    Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
    Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choroid plexus volume as a marker of retinal atrophy in relapsing remitting multiple sclerosis.
    Raghib MF; Bao F; Elkhooly M; Bernitsas E
    J Neurol Sci; 2024 Feb; 457():122884. PubMed ID: 38237367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Button J; Al-Louzi O; Lang A; Bhargava P; Newsome SD; Frohman T; Balcer LJ; Frohman EM; Prince J; Calabresi PA; Saidha S
    Neurology; 2017 Feb; 88(6):525-532. PubMed ID: 28077493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.
    Saidha S; Al-Louzi O; Ratchford JN; Bhargava P; Oh J; Newsome SD; Prince JL; Pham D; Roy S; van Zijl P; Balcer LJ; Frohman EM; Reich DS; Crainiceanu C; Calabresi PA
    Ann Neurol; 2015 Nov; 78(5):801-13. PubMed ID: 26190464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    Filippi M; Pagani E; Turrini R; Bartezaghi M; Brescia Morra V; Borriello G; Torri Clerici V; Mirabella M; Pasquali L; Patti F; Totaro R; Gallo P; Rocca MA;
    J Neurol; 2024 Sep; 271(9):6181-6196. PubMed ID: 39073436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline retinal nerve fiber layer thickness as a predictor of multiple sclerosis progression: New insights from the FREEDOMS II study.
    Wang L; Tan H; Yu J; ZhangBao J; Huang W; Chang X; Zhou L; Lu C; Xiao Y; Lu J; Zhao C; Wang M; Wu X; Wu M; Dong Q; Ngew KY; Quan C
    Eur J Neurol; 2023 Feb; 30(2):443-452. PubMed ID: 36286605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
    Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Lambe J; Risher H; Filippatou AG; Murphy OC; Sotirchos ES; Ehrhardt H; Ogbuokiri E; Pellegrini N; Toliver B; Luciano NJ; Davis S; Fioravante N; Kwakyi O; Prince JL; Calabresi PA; Fitzgerald KC; Saidha S
    Neurology; 2021 May; 96(20):e2525-e2533. PubMed ID: 33827962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis-Evidence for applying a rebaselining concept.
    Bsteh G; Hegen H; Krajnc N; Föttinger F; Altmann P; Auer M; Berek K; Kornek B; Leutmezer F; Macher S; Monschein T; Ponleitner M; Rommer P; Schmied C; Zebenholzer K; Zulehner G; Zrzavy T; Deisenhammer F; Di Pauli F; Pemp B; Berger T
    Mult Scler; 2024 Aug; 30(9):1128-1138. PubMed ID: 39109593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    Weeda MM; van Nederpelt DR; Twisk JWR; Brouwer I; Kuijer JPA; van Dam M; Hulst HE; Killestein J; Barkhof F; Vrenken H; Pouwels PJW
    J Neurol; 2024 Jan; 271(1):355-373. PubMed ID: 37716917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.